A Polymeric Nanocarrier That Eradicates Breast Cancer Stem Cells and Delivers Chemotherapeutic Drugs

Overview

Journal Biomater Res

Specialty Biomedical Engineering

Date 2023 Dec 16

PMID 38102651

Authors

Li Lv

Yonghui Shi

Zhicheng Deng

Jiajia Xu

Zicong Ye

Jianxiong He

Guanghui Chen

Xiaoxia Yu

Junyan Wu

Xingzhen Huang

Guocheng Li

Affiliations

Soon will be listed here.

Abstract

Background: Drug nanocarriers can markedly reduce the toxicities and side effects of encapsulated chemotherapeutic drugs in the clinic. However, these drug nanocarriers have little effect on eradicating breast cancer stem cells (BCSCs). Although compounds that can inhibit BCSCs have been reported, these compounds are difficult to use as carriers for the widespread delivery of conventional chemotherapeutic drugs.

Methods: Herein, we synthesize a polymeric nanocarrier, hyaluronic acid-block-poly (curcumin-dithiodipropionic acid) (HA-b-PCDA), and explore the use of HA-b-PCDA to simultaneously deliver chemotherapeutic drugs and eradicate BCSCs.

Results: Based on molecular docking and molecular dynamics studies, HA-b-PCDA delivers 35 clinical chemotherapeutic drugs. To further verify the drug deliver ability of HA-b-PCDA, doxorubicin, paclitaxel, docetaxel, gemcitabine and camptothecin are employed as model drugs to prepare nanoparticles. These drug-loaded HA-b-PCDA nanoparticles significantly inhibit the proliferation and stemness of BCSC-enriched 4T1 mammospheres. Moreover, doxorubicin-loaded HA-b-PCDA nanoparticles efficiently inhibit tumor growth and eradicate approximately 95% of BCSCs fraction in vivo. Finally, HA-b-PCDA eradicates BCSCs by activating Hippo and inhibiting the JAK2/STAT3 pathway.

Conclusion: HA-b-PCDA is a polymeric nanocarrier that eradicates BCSCs and potentially delivers numerous clinical chemotherapeutic drugs.

Citing Articles

Targeted multimodal synergistic therapy of drug-resistant HER2-positive breast cancer by pyrotinib-ICG self-assembled nanoparticles.

Xuhong J, Wu N, Shi Q, Tian H, Peng Z, Jiang J Am J Cancer Res. 2024; 14(8):3976-3993.

PMID: 39267659 PMC: 11387853. DOI: 10.62347/JZRN6919.

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways.

Li D, Shao F, Yu Q, Wu R, Tuo Z, Wang J Cell Commun Signal. 2024; 22(1):405.

PMID: 39160622 PMC: 11331645. DOI: 10.1186/s12964-024-01776-7.

Epigenetic clocks and gliomas: unveiling the molecular interactions between aging and tumor development.

Chen S, Jiang Y, Wang C, Tong S, He Y, Lu W Front Mol Biosci. 2024; 11:1446428.

PMID: 39130373 PMC: 11310061. DOI: 10.3389/fmolb.2024.1446428.

References

Liu Y, Zhu C, Tang L, Chen Q, Guan N, Xu K . MYC dysfunction modulates stemness and tumorigenesis in breast cancer. Int J Biol Sci. 2021; 17(1):178-187. PMC: 7757029. DOI: 10.7150/ijbs.51458. View

Du W, Yang X, He S, Wang J, Guo Y, Kou B . Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer. Drug Deliv. 2021; 28(1):920-929. PMC: 8118506. DOI: 10.1080/10717544.2021.1914777. View

Lv L, Shi Y, Wu J, Li G . Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting. Int J Nanomedicine. 2021; 16:1487-1508. PMC: 7914063. DOI: 10.2147/IJN.S282110. View

Zou H, Luo J, Guo Y, Liu Y, Wang Y, Deng L . RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7. Oncogene. 2022; 41(11):1657-1672. PMC: 8913359. DOI: 10.1038/s41388-022-02198-w. View

Sardao V, Oliveira P, Holy J, Oliveira C, Wallace K . Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol. 2008; 25(3):227-43. DOI: 10.1007/s10565-008-9070-1. View

Fraczkowska K, Bacia M, Przybylo M, Drabik D, Kaczorowska A, Rybka J . Alterations of biomechanics in cancer and normal cells induced by doxorubicin. Biomed Pharmacother. 2017; 97:1195-1203. DOI: 10.1016/j.biopha.2017.11.040. View

Keam B, Lee K, Lee S, Kim J, Kim J, Wu H . A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist. 2019; 24(6):751-e231. PMC: 6656523. DOI: 10.1634/theoncologist.2019-0070. View

Li H, Yan W, Suo X, Peng H, Yang X, Li Z . Nucleus-targeted nano delivery system eradicates cancer stem cells by combined thermotherapy and hypoxia-activated chemotherapy. Biomaterials. 2019; 200:1-14. DOI: 10.1016/j.biomaterials.2019.01.048. View

Chen H, Yang J, Yang Y, Zhang J, Xu Y, Lu X . The Natural Products and Extracts: Anti-Triple-Negative Breast Cancer in Vitro. Chem Biodivers. 2021; 18(7):e2001047. DOI: 10.1002/cbdv.202001047. View

10.

Zhou H, Yan J, Chen W, Yang J, Liu M, Zhang Y . Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. Front Oncol. 2021; 10:1731. PMC: 7892953. DOI: 10.3389/fonc.2020.01731. View

11.

Nagykalnai T . [Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin]. Magy Onkol. 2010; 54(4):359-67. DOI: 10.1556/MOnkol.54.2010.4.10. View

12.

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

13.

Yang Z, Sun N, Cheng R, Zhao C, Liu J, Tian Z . Hybrid nanoparticles coated with hyaluronic acid lipoid for targeted co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. J Mater Chem B. 2020; 5(33):6762-6775. DOI: 10.1039/c7tb01510k. View

14.

Mei X, Li X, Zhao C, Liu A, Ding Y, Shen C . The Use of Molecular Dynamics Simulation Method to Quantitatively Evaluate the Affinity between HBV Antigen T Cell Epitope Peptides and HLA-A Molecules. Int J Mol Sci. 2022; 23(9). PMC: 9105472. DOI: 10.3390/ijms23094629. View

15.

Liu S, Huang C, Bamodu O, Lin C, Liu B, Tzeng Y . Ovatodiolide suppresses nasopharyngeal cancer by targeting stem cell-like population, inducing apoptosis, inhibiting EMT and dysregulating JAK/STAT signaling pathway. Phytomedicine. 2019; 56:269-278. DOI: 10.1016/j.phymed.2018.05.007. View

16.

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View

17.

Jiang Q, Lin Z, Su Z, Li S, Li J, Guan S . Peptide identification of hepatocyte growth-promoting factor and its function in cytoprotection and promotion of liver cell proliferation through the JAK2/STAT3/c-MYC pathway. Eur J Pharmacol. 2022; 920:174832. DOI: 10.1016/j.ejphar.2022.174832. View

18.

Yao H, Zhang Y, Sun L, Liu Y . The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014; 35(33):9208-23. DOI: 10.1016/j.biomaterials.2014.07.033. View

19.

Zhu Q, Sun F, Li T, Zhou M, Ye J, Ji A . Engineering Oxaliplatin Prodrug Nanoparticles for Second Near-Infrared Fluorescence Imaging-Guided Immunotherapy of Colorectal Cancer. Small. 2021; 17(13):e2007882. DOI: 10.1002/smll.202007882. View

20.

Zang S, Liu T, Shi J, Qiao L . Curcumin: a promising agent targeting cancer stem cells. Anticancer Agents Med Chem. 2014; 14(6):787-92. DOI: 10.2174/1871520614666140521114735. View